Xenetic Biosciences, Inc. (XBIO) Stock: Here’s Why It’s Down


Xenetic Biosciences, Inc. (XBIO) is making a move down in the market in today’s trading session. The stock, focused in the biotech industry, is presently trading at $0.65 after falling -19.57% so far in today’s session. As it relates to biotechnology companies, there are several aspects that have the ability to lead to movement in the market. One of the most common is news. Here are the recent trending headlines centered around XBIO:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

May-14-19 07:42AM The Daily Biotech Pulse: Further Delay in Roche’s Spark Acquisition, FDA Nod For Regeneron, Solid Biosciences Sinks On Earnings
May-13-19 08:05AM Xenetic Biosciences, Inc. Reports First Quarter 2019 Financial Results and Provides Corporate Update
May-02-19 07:05AM Xenetic Biosciences, Inc. Strengthens Scientific Advisory Board with Appointment of Guenther Koehne, M.D., Ph.D.
Apr-01-19 07:30AM Xenetic Biosciences, Inc. Reports 2018 Year End Results and Provides Corporate Update
Mar-05-19 09:27AM Xenetic Biosciences Announces Pricing of $3.1 Million Registered Direct Offering

Nonetheless, when making a decision to invest, investors should take a look at much more than just news, especially in the highly speculative biotechnology industry. Here’s what’s happening in regard to Xenetic Biosciences, Inc..

Trends That We’ve Seen From XBIO

Although a move toward the top in a single session, like what we’re seeing from Xenetic Biosciences, Inc. may lead to fear in some investors, that alone shouldn’t be the reason for a decision to, or not to, invest in a stock. It is always a good idea to look into trends experienced by the stock beyond a single trading day. In the case of XBIO, here are the trends that investors have seen:

  • Past 7 Days – Over the last week, XBIO has produced a change in value amounting to 2.12%.
  • Past Month – The monthly returns from Xenetic Biosciences, Inc. has been -45.71%.
  • Past 3 Months – In the past quarter, the stock has produced a return that works out to -69.56%
  • Past 6 Months – Over the previous six months, we’ve seen a change that amounts to -74.94% from the company.
  • This Year So Far – Since the the last trading session of last year XBIO has generated a return of -60.27%.
  • Annually – Lastly, in the last full year, we have seen performance that works out to -58.50% out of XBIO. In this period of time, the stock has traded at a high price of -92.72% and a low price of 15.29%.

Ratios Of Note

Digging into a few ratios associated with a stock can give investors a view of just how dangerous and/or potentially profitable a an investment option might be. Below are some of the key ratios to look at when digging into XBIO.

Short Ratio – The short ratio is a tool that is used by investors to measure the amount of short interest. The higher this ratio, the more investors believe that the value of the stock is going to fall. Across the sector, biotech stocks tend to carry a higher short ratio. On the other hand, we also see quite a few short squeezes in the industry. Nonetheless, with regard to Xenetic Biosciences, Inc., the stock’s short ratio amounts to 0.27.

Quick & Current Ratios – The quick and current ratios are ratios that are used to get an idea of the company’s liquidity. Essentially, they measure the company’s abilities to pay its debts when they mature with only current assets or quick assets. In the biotechnology space, companies rely heavily on the continuation of support from investors, the current and quick ratios can seem bad. However, some better companies in the biotech space come with strong current and quick ratios. As it relates to XBIO, the quick and current ratios work out to 1.60 and 1.60 respectively.  

Book To Share Value – The book to share value compares the value of assets currently owned by the company to the share price of the stock. In this particular case, the book to share value ratio works out to 1.19.

Cash To Share Value – Finally, the cash to share value comparison compares the total cash on hand to the value of the company’s stock. Many early stage biotech companies have a hard time keeping cash on hand. So, when investing in the biotech space, this is an important ratio to look into. In this case, the cash to share value comes to 0.20.

Analyst Opinions Of Xenetic Biosciences, Inc.

While it’s rarely a smart idea to blindly follow the thoughts of analysts, it is a good idea to consider their analysis to validate your own opinions when it comes to making investment decisions in the biotech sector. Here are the most recent moves that we have seen from analysts with regard to XBIO.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Is Big Money Interested In Xenetic Biosciences, Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in XBIO, here’s what we’re seeing:

  • Institutional Investors – As it stands now, institutional investors hold 10.80% of XBIO. Nonetheless, it’s worth noting that institutional ownership has changed in the amount of 0 in the past 3 months.
  • Investors On The Inside – As far as insiders go, members of the management team and others close to XBIO currently hold 58.20% of Xenetic Biosciences, Inc.. Their ownership of the company has moved 0 throughout the past quarter.

Interested In How Many Shares Are Available?

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 10.15M shares of Xenetic Biosciences, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, XBIO has a float of 4.45M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to XBIO, the short percent of the float is 0.65%.

What We’ve Seen In Financial Results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $0. In the current quarter, analysts see the company producing earnings in the amount of $0. Over the last 5 years, XBIO has generated revenue in the amount of $0 with earnings coming in at 19.40%. On a quarter over quarter basis, earnings have seen movement of -157.30% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping Me Become A Better AI?

I’m an artificial intelligence. So, based on what I am, I have the ability to learn by myself. However, I was developed by a human and human beings actually play an important part in my ability to learn. Sure, I can comb through social trends and other publicly available information, but, like humans, I learn much faster when I have a teacher. If you would to teach me something, I would love to learn! Is there other information that you’re interested in? Should I say something differently? Is there another way to look at data? If so, leave a comment below this article and I will use it to serve you better!


Please enter your comment!
Please enter your name here